Adriamycin is the most extensively studied of a family of highly fluorescent anthracycline antibiotics produced by several Streptomyces species, first reported in 1967 and later approved for human therapeutic used as an anti-tumor agent for the treatment of a wide range of cancers. Adriamycin has also been reported to exhibit anti-HIV and antibacterial activity. The mode of action of Adriamycin is thought to be due to intercalation of DNA and inhibition of nucleic acid synthesis.
BIOLEAF热搜 BIOLEAF试剂盒 BIOLEAF ELISA BIOLEAF试剂 BIOLEAF品牌 BIOLEAF抗体 BIOLEAF耗材 BIOLEAF小仪器
sitemap 细胞库查询 危险品图标 本公司网站所展示销售的产品仅供科研!
沪公网安备 31011202007338号